Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Inclusion Criteria: * Age ≥ 18 years * Histologic proof of melanoma reviewed and confirmed at MSKCC * Patients must have stage IV melanoma or recurrent stage IIIb or IIIc melanoma. Patients who are potentially respectable will be eligible. * Measurable disease (RECIST criteria). Patients must have a tumor amenable to biopsy for oligonucleotide microarray analysis and for immunohistochemistry. A pre-treatment biopsy is required; a fine needle aspirate is not adequate. * No prior cytotoxic chemotherapy for melanoma. Prior immunotherapy or anti-angiogenic therapy is allowed. * No other concurrent chemotherapy, immunotherapy, or radiotherapy * ECOG performance status ≤ 1 * Adequate organ function defined as follows: ANC \>1500/mm3, Platelets \>130,000/mm3, calculated creatinine clearance ≥60 ml/minute (Cockcroft \& Gault). * Adequate cardiac function to tolerate the hydration needed for cisplatin administration. Exclusion Criteria: * History of CNS metastases unless brain metastases have been resected or successfully treated with stereotactic radiosurgery and the patient has been free from CNS recurrence for 3 months. * Uveal melanoma primary * Patients who have had prior anti-CTLA4 monoclonal antibody treatment must have been off treatment for at least 4 months and have signs of progression of disease. * Frequent vomiting or medical conditions that could interfere with oral medication intake * Serious infection requiring antibiotics, or nonmalignant medical illnesses that are uncontrolled or whose control might be jeopardized by the complications of this therapy. * History of HIV infection even if on HAART * Immunosuppressive drugs * High dose vitamins and herbs * Other on-going investigational therapy, concurrent chemotherapy, immunotherapy or radiotherapy.